Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19

ARDS Due to COVID-19 Clinical Trial

Official title: Open-label Trial to Assess the Efficacy and Safety of Inhalation Use of the Approved Drug Surfactant-BL (Biosurf LLC, Russia) as a Part of Complex Therapy of Acute Respiratory Distress Syndrome (ARDS) in Patients With SARS-CoV-2 Coronavirus Infection (COVID-19)

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.

Clinical Trial Description

The efficacy and safety of Surfactant-BL will be evaluated in terms of mean duration of oxygen therapy (days) after hospitalization, in adult patients with ARDS due to SARS-COV-19 infection.

Adult patients with COVID-19 induced respiratory failure will be receive either standard treatment or standard treatment plus Surfactant-BL. ;

Related Conditions & MeSH terms

• Acute Lung Injury
• ARDS Due to COVID-19
• Respiratory Distress Syndrome, Adult
• Respiratory Distress Syndrome, Newborn

• NCT number: NCT04568018
• Study type: Observational
• Source: Biosurf LLC.
• Status: Active, not recruiting
• Start date: July 3, 2020
• Completion date: December 2021